KEI asks WHO to include risdiplam, treatment for Spinal Muscular Atrophy, on the Essential Medicines List (EML)
EML
WHO expands the list of essential medicines and proposes a new working group to address ways to make highly priced essential medicines more affordable and accessible.
On October 1, 2021, the WHO published the new edition of its Model Lists (the EML) of Essential Medicines and Essential Medicines for Children. WHO Documents Press Release Executive Summary World Health Organization model list of essential medicines: 22nd list… Continue Reading
KEI submissions to the WHO Model Lists of Essential Medicines (EML)
KEI submissions to the WHO Model List of Essential Medicines (EML) 14 January 2013, Knowledge Ecology International (KEI), the University of California (San Francisco), Universities Allied for Essential Medicines (UAEM), Third World Network (TWN) and Young Professionals Chronic Disease Network:… Continue Reading
KEI statement: 22nd meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines
On Monday, 1 April 2019, Knowledge Ecology International (KEI) delivered the following oral statement to the Open Session of the 22nd Meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines. The program for the open… Continue Reading
KEI Submission to WHO Essential Medicines List – Enzalutamide / Abiraterone Acetate
The WHO Essential Medicines List is a major WHO tool used to expand access to medicines. In 2017, the WHO issued the 20th Essential Medicines List (EML) which was the 40th anniversary of the list. The WHO is currently in… Continue Reading
January 2013: Proposal for the inclusion of trastuzumab in WHO EML for treatment of HER2-Positive Breast Cancer
On 14 January 2013, Knowledge Ecology International (KEI), the University of California (San Francisco), Universities Allied for Essential Medicines (UAEM), Third World Network (TWN) and Young Professionals Chronic Disease Network: YP-CDN submitted a Proposal for the Inclusion of Trastuzumab in the WHO Model List of Essential Medicines for the Treatment of HER2-Positive Breast Cancer to WHO’s Exper Continue Reading
Call for Action on Cancer Drugs by YP-CDN, KEI, and UAEM at 67th World Health Assembly
At the opening of the 67th World Health Assembly, today the Young Professionals Chronic Disease Network (YP-CDN), Knowledge Ecology International (KEI), and Universities Allied for Essential Medicines (UAEM) released a briefing, “Cancer medicines are essential in reducing the global burden of non-communicable diseases.”
Approval, ownership, market structure, and placement on WHO EML for 100 new cancer NMEs on NCI alpha list
KEI research associate Paul Miano has written the following paper: Cancer: Approval, ownership, market structure, and placement on WHO Model Essential Medicines List, for 100 new molecular entities (NMEs) on the NCI alpha list of cancer drugs and vaccines. KEI Research Note 2011:1,
A full copy of the paper is available in PDF format here.
The following is from the introduction (sans footnotes, which are in the PDF version):
Introduction and Summary
2007 KEI Letter to WHO on the Essential Medicines List
March 2, 2007 Secretary of the Expert Committee on the Selection and Use of Essential Medicines (2007)Department of Medicines Policy and Standards (PSM)Health Technology & PharmaceuticalsWorld Health OrganizationCH-1211 Geneva 27Switzerland Via e-mail: emisecretariat@who.int RE: Request for changes in the WHO Model… Continue Reading
Letter asking WHO review of the Essential Drugs List (EDL) as it relates to patented products
The following is the text of a letter to Dr. Margaret Chan, Director-General Elect, World Health Organization (WHO), asking for a review of the Essential Drugs List (EDL) as it relates to patented products. Consumer Project on Technology http://www.cptech.org December… Continue Reading